GlassScriptPhysician profile
Adam Kichler
NPI 1487997623
$1,225.80
in general payments reported to CMS, 2019-2025
15 companies · $304 in 2025
The $304 reported for 2025 was more than what 84% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2021: $56.20 · 2022: $256 · 2023: $99.85 · 2024: $258 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645 · Education: $17.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.79 |
| Education | $17.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $368.12 | 2019-2024 | Spyglass, X-Tack Endoscopic Helix Tacking System, Cre Pro |
| Takeda Pharmaceuticals U.S.A., INC. | $165.58 | 2019-2025 | Entyvio |
| Steris Corporation | $158.48 | 2025 | |
| Abbvie INC. | $106.31 | 2021-2025 | |
| Fujifilm Healthcare Americas Corporation | $85.00 | 2024 | |
| Gilead Sciences, INC. | $80.13 | 2019 | |
| Olympus America INC. | $55.36 | 2019 | |
| Janssen Biotech, INC. | $49.59 | 2025 | Tremfya |
| Genzyme Corporation | $46.01 | 2023-2024 | |
| Vivus LLC | $22.27 | 2024 | Qsymia |
| Apollo Endosurgery US INC | $22.06 | 2023 | Overstitch Endoscopic Suturing System |
| Lilly USA, LLC | $18.33 | 2024 | Omvoh |
| Celltrion USA INC. | $17.62 | 2023 | Yuflyma |
| Ardelyx, INC. | $15.65 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $15.29 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Kichler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.